PPT-CDK 4/6 Inhibitors in Breast Cancer Expert Perspectives on New Data

CDK 46 Inhibitors in Breast Cancer Expert Perspectives on New Data Faculty Javier Cortes MD PhD Head Breast Cancer Program Oncology Department Ramon y Cajal University Hospital Madrid Spain. and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Trial Portfolio. Any Receptor Status. Triple Negative. Clinical Trial Contacts. A content placeholder. Use for text, graphics, tables and graphs. You can change this text or delete it.. Here is a placeholder for more text. You may delete this text. What’s Positive about Triple Negative Breast Cancer ? Julie R. Gralow, M.D. Jill Professor Endowed Professor of Breast Cancer Director, Breast Medical Oncology Seattle Cancer Care Alliance University of Washington School of Medicine Targeting endocrine-resistance pathways in breast cancer Clara Natoli, Chieti Endocrine responsive breast cancer Luminal A High expression of ER & ER-related genes Lower An Interactive Oncology Grand Rounds Series. Joyce O’Shaughnessy, MD. Chair, Breast Cancer Research Program. Baylor Charles A Sammons Cancer Center. Celebrating Women Chair in Breast Cancer Research. Joel Brothers. 10/4/2016. Understand the indications and benefits of bisphosphonates in metastatic disease: . Breast Cancer. Prostate Cancer. Multiple Myeloma. Other Solid Malignancies. 2) Understand the role of bisphosphonates/. Audience. : . GenEd. Biology . students. Linda Grisham, Massachusetts Bay Community College. Mark Maloney, Spelman College. Kim . Gernert. , Emory University . Inspired by the recent Angelina Jolie health . Medication Teaching The Center for Breast Cancer Mass General Cancer Center 2 Topics to Discuss • What are Aromatase Inhibitors? How do they work in the body? • Reasons for taking an Aromatase I tablet the next day.Aromatase inhibitors can interact with other medications specialist or doctor.Always tell any other doctor, dentist or pharmacist inhibitor.oestrogen in the body, it is possible to Confluenceinternationalresearchproject-a consortiumconsortiathataimsto build a largecollaborativeplatformforgermlinegeneticstudiesbreastcancer GoalsConduct a large, multi Breast Cancer Cases Controls ��Letrozole(Breast)��UM Comprehensive Cancer CentertrozoleHormonal TherapyWhat are Aromatase Inhibitors?Aromatase inhibitors are drugs that are sometimes used to treat brea 1 of 15 and management of oestrogen deciency symptoms and arthralgia in women treated for breast cancer Key points 1. An early menopause, estrogen deciency symptoms and arthralgia are common s Key recommendations. 1. National and local workforce planning is essential. Health Education England and all Cancer Alliances should urgently ensure there are enough healthcare professionals to deliver high-quality and timely diagnosis, treatment and care to local women..